Here are nine key points:
1. DJO’s net sales increased by 4.6 percent to $292.9 million, compared to $279.9 million in the second quarter of 2015.
2. The company’s adjusted EBITDA hit $63.6 million, a 3.7 percent increase from the same period the year prior.
3. DJO saw a net loss of $23.3 million during the second quarter, compared to a net loss of $78 million in the same period the year prior.
4. DJO’s bracing and vascular segment net sales hit $131.8 million, down 3.3 percent from the second quarter of 2015. The company believes delivery complications resulted in this drop.
5. The recovery sciences segment net sales reached $38.4 million, a 4.1 percent decrease compared to the same period a year prior.
6. The company’s international segment net sales totaled $80.1 million, a 6 percent increase from the second quarter of 2015. DJO’s shoulder, knee and hip product lines spurred this growth.
7. DJO’s cash balances equal $41.7 million and its available liquidity is $67.5 million under the $150 million revolving credit facility.
8. DJO anticipates growth in its top line and constant currency revenue growth rates of 6 percent.
9. Looking ahead, the company expects adjusted EBITDA growth rate between 8 percent and 10 percent for 2016.
More articles on devices:
Paul Thomas newest addition to Cohera Medical’s board of directors: 5 highlights
Globus Medical to acquire Alphatec Holdings’ international business for $80M — 9 key insights
DeGen Medical’s F1 MPS Modular Pedicle Screw System for JOUST MIS procedure receives FDA approval: 4 things to know
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
